Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 8c, Revenues Miss; Offers FY19 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. CVS
8. SBUX
9. AXP
10. ZETA

Go back to Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 8c, Revenues Miss; Offers FY19 Revenue Outlook

Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results

May 1, 2019 4:01 PM EDT

WASHINGTON, May 1, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2019.

"During the first quarter, Vanda made significant advances towards its commercial and research goals. Patients on treatment with Hetlioz continue to increase steadily, driven by broader awareness and recognition of Non-24. We are preparing for a possible launch later this year in jet lag disorder, an indication that has the potential to drive significant growth for our Hetlioz franchise. Tradipitant clinical development is advancing for three indications, atopic... More